Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Q3 Revenue Up 10 Percent on Increased LAS Business

NEW YORK, Oct. 29 (GenomeWeb News) - PerkinElmer said today that increasing revenues in its Life and Analytical Sciences division offset lower biopharma receipts and helped the company post a 10-percent jump in third-quarter revenue.

Total receipts for the period ended Sept. 30 increased to $403 million from $366 million one year ago. Revenue from the company's Life and Analytical Sciences division, which offers products for genetic screening, service, and environment, grew 4 percent, to $243.7 million from $235.1 million.

 

PerkinElmer's life and analytical sciences business reported revenues of $244 million for the period, up from $235 million for the third quarter in 2003.


Research and development expenses were $21 million for the period, up from $20 million for the same quarter in 2003.

 

Net income during the quarter surged to $24 million, or $. 19 per share, from $14 million, or $.11 per share, in the year-ago quarter.

 

The company reported cash and cash equivalents of $220 million on hand at the end of the quarter.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.